Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.
The common Z mutation (Glu342Lys) of α1-antitrypsin (A1AT) results in the polymerization and intracellular retention of A1AT protein. The concomitant deficiency of functional A1AT predisposes PiZZ subjects to early onset emphysema. Clinical studies have implied that, among the biomarkers associated...
Main Authors: | Janine Koepke, Marc Dresel, Severin Schmid, Timm Greulich, Björn Beutel, Bernd Schmeck, Claus Franz Vogelmeier, Sabina Janciauskiene, Andreas Rembert Koczulla |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4311911?pdf=render |
Similar Items
-
Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine release
by: Westin Ulla, et al.
Published: (2005-01-01) -
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
by: Schmid ST, et al.
Published: (2012-09-01) -
Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis
by: Timm Greulich, et al.
Published: (2016-02-01) -
Does Augmentation with Alpha1-Antitrypsin Affect Neutrophil Extracellular Traps Formation?
by: Eileen Frenzel, Elena Korenbaum, Jan Hegermann, Matthias Ochs, Janine Koepke, Andreas Rembert Koczulla, Tobias Welte, Thomas Köhnlein, Sabina Janciauskiene
Published: (2012-01-01) -
How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?
by: Ilaria Ferrarotti, et al.
Published: (2015-01-01)